2,790
Views
1
CrossRef citations to date
0
Altmetric
Research Paper

Cloning and codon optimization of a novel feline interferon omega gene for production by Pichia pastoris and its antiviral efficacy in polyethylene glycol-modified form

, , , ORCID Icon, , , , ORCID Icon & ORCID Icon show all
Pages 297-309 | Received 25 Nov 2021, Accepted 11 Jan 2022, Published online: 24 Jan 2022

References

  • Sedger LM. MicroRNA control of interferons and interferon induced anti-viral activity. Mol Immunol. 2013;56(4):781–793.
  • Russell KD, Sergei VK, Joan ED. Interferon induction and function at the mucosal surface. Immunol Rev. 2013;255(1):25–39.
  • Mou C, Pan S, Wu H, et al. Disruption of interferon-β production by the N pro of atypical porcine pestivirus. Virulence. 2021;12(1):654–665.
  • Fanunza E, Carletti F, Quartu M, et al. Zika virus NS2A inhibits interferon signaling by degradation of STAT1 and STAT2. Virulence. 2021;12(1):1580–1596.
  • Shang J, Zheng Y, Mo J, et al. Sox4 represses host innate immunity to facilitate pathogen infection by hijacking the TLR signaling networks. Virulence. 2021;12(1):704–722.
  • Lin JD, Feng N, Sen A, et al. Distinct roles of type I and type III interferons in intestinal immunity to homologous and heterologous rotavirus infections. PloS Pathog. 2016;12(4):e1005600.
  • Minayoshi Y, Maeda H, Yanagisawa H, et al. Development of Kupffer cell targeting type-I interferon for the treatment of hepatitis via inducing anti-inflammatory and immunomodulatory actions. Drug Deliv. 2018;25(1):1055–1065.
  • Platanias LC. Mechanisms of type I and type II interferon-mediated signaling. Nat Rev Immunol. 2005;5(5):375–386.
  • Lopusna K, Rezuchova I, Betakova T, et al. Interferons lambda, new cytokines with antiviral activity. Acta Virol. 2013;57(2):171–179.
  • Gao D, Yu X, Zhang B, et al. Role of autophagy in inhibiting the proliferation of A549 cells by type III interferon. Cell Biol Int. 2019;43(6):605–612.
  • Stuetzer B, Hartmann K. Feline parvovirus infection and associated diseases. Vet J. 2014;201(2):150–155.
  • Cheng N, Zhao Y, Han Q, et al. Development of a reverse genetics system for a feline panleukopenia virus. Virus Genes. 2019;55(1):95–103.
  • Cave T, Thompson H, Reid S, et al. Kitten mortality in the United Kingdom: a retrospective analysis of 274 histopathological examinations (1986 to 2000). Vet Rec. 2002;151(17):497–501.
  • Domenech A, Miro G, Collado VM, et al. Use of recombinant interferon omega in feline retrovirosis: from theory to practice. Vet Immunol Immunopathol. 2011;143(3–4):301–306.
  • Freaney JE, Zhang Q, Yigit E, et al. High density nucleosome occupancy map of human chromosome 9p21-22 reveals chromatin organization of the type I interferon gene cluster. J Interf Cytok Res. 2014;34(9):676–685.
  • Xu C, Song X, Fu L, et al. Antiviral potential of exogenous human omega interferon to inhibit pandemic 2009 A (H1N1) influenza virus. Viral Immunol. 2011;24(5):369–374.
  • Yang LM, Xue QH, Sun L, et al. Cloning and characterization of A Novel feline IFN-ω. J Interf Cytok Res. 2007;27(2):119–127.
  • Wang X, Li F, Han M, et al. Cloning, prokaryotic soluble expression, and analysis of antiviral activity of two novel feline IFN-ω proteins. Viruses. 2020;12(3):335.
  • Sang Y, Rowland RR, Hesse RA, et al. Differential expression and activity of the porcine type I interferon family. Physiol Genomics. 2010;42(2):248–258.
  • Detournay O, Morrison DA, Wagner B, et al. Genomic analysis and mRNA expression of equine type I interferon genes. J Interf Cytok Res. 2013;33(12):746–759.
  • Seo Y, Kim M, Choi M, et al. Possible role of phosphoinositide-3-kinase in Mx1 protein translation and antiviral activity of interferon-omega-stimulated HeLa cells. Pharmacology. 2011;87(3–4):224–231.
  • Klarquist J, Cantrell R, Lehn MA, et al. Type I IFN drives experimental systemic lupus erythematosus by distinct mechanisms in CD4 T cells and B cells. Immunohorizons. 2020;4(3):140–152.
  • de Mari K, Maynard L, Sanquer A, et al. Therapeutic effects of recombinant feline interferon-omega on feline leukemia virus (FeLV)-infected and FeLV/feline immunodeficiency virus (FIV)-coinfected symptomatic cats. J Vet Intern Med. 2004;18(4):477–482.
  • Leal RO, Gil S, Duarte A, et al. Evaluation of viremia, proviral load and cytokine profile in naturally feline immunodeficiency virus infected cats treated with two different protocols of recombinant feline interferon omega. Res Vet Sci. 2015;99:87–95.
  • Skorvanova L, Svancarova P, Svetlikova D, et al. Protective efficacy of IFN-ω AND IFN-λs against influenza viruses in induced A549 cells. Acta Virol. 2015;59(4):413–417.
  • Du Y, Tian H, Gao XD, et al. Pharmacokinetic properties of a 40 kDa branched polyethylene glycol-modified form of consensus interferon-α (PEG-CIFN) in Rhesus monkeys. Biopharm Drug Dispos. 2008;29(8):481–484.
  • Leal RO, Gil S, Sepúlveda N, et al. Monitoring acute phase proteins in retrovirus infected cats undergoing feline interferon-ω therapy. J Small Anim Pract. 2014;55(1):39–45.
  • Matsumoto H, Teshima T, Iizuka Y, et al. Evaluation of the efficacy of the subcutaneous low recombinant feline interferon-omega administration protocol for feline chronic gingivitis-stomatitis in feline calicivirus-positive cats. Res Vet Sci. 2018;118:324–330.
  • Liu Y, Liu X, Kang H, et al. Identification of feline interferon regulatory factor 1 as an efficient antiviral factor against the replication of feline calicivirus and other feline viruses. Biomed Res Int. 2018;8:1–10.
  • Fiorito F, Cantiello A, Granato GE, et al. Clinical improvement in feline herpesvirus 1 infected cats by oral low dose of interleukin-12 plus interferon-gamma. Comp Immunol Microbiol Infect Dis. 2016;48:41–47.
  • Vincentelli R, Canaan S, Campanacci V, et al. High-throughput automated refolding screening of inclusion bodies. Protein Sci. 2004;13(10):2782–2792.
  • Feng Y, Zhang M, Zhang L, et al. An automatic refolding apparatus for preparative-scale protein production. PLoS ONE. 2012;7(9):e45891.
  • Cregg JM, Cereghino JL, Shi J. Recombinant protein expression in Pichia pastoris. Mol Biotechnol. 2000;16(1):23–52.
  • Wang QH, Gao LL, Liang HC, et al. [Research advances of the influence factors of high level expression of recombinant protein in Pichia pastoris]. Acta Pharma Sin. 2014;49(12):1644–1649.
  • Baghban R, Farajnia S, Ghasemi Y, et al. New developments in Pichia pastoris expression system, review and update. Curr Pharm Biotechnol. 2018;19(6):451–467.
  • Xu Y, Liu K, Han Y, et al. Codon usage bias regulates gene expression and protein conformation in yeast expression system P. pastoris. Microb Cell Fact. 2021;20(1):91.
  • Kudla G, Lipinski L, Caffin F, et al. High guanine and cytosine content increases mRNA levels in mammalian cells. PLoS Biol. 2006;4(6):e180.
  • Kiktev DA, Sheng Z, Lobachev KS, et al. GC content elevates mutation and recombination rates in the yeast Saccharomyces cerevisiae. Proc Natl Acad Sci. 2018;115(30):E7109–E7118.
  • Scott VL, Shack LA, Eells JB, et al. Immunomodulator expression in trophoblasts from the feline immunodeficiency virus (FIV)-infected cat. Virol J. 2011;8(1):336.
  • Shields LE, Jennings J, Liu Q, et al. Cross-species genome-wide analysis reveals molecular and functional diversity of the unconventional interferon-ω subtype. Front Immunol. 2019;10:1431.
  • Gao M, Guo Y, Luo X, et al. Design, biological activity and signaling pathway of bovine consensus omega interferon expressed in Pichia pastoris. Mol Immunol. 2019;106:46–52.
  • Taglinger K, Van Nguyen N, Helps CR, et al. Quantitative real-time RT-PCR measurement of cytokine mRNA expression in the skin of normal cats and cats with allergic skin disease. Vet Immunol Immunopathol. 2008;122(3–4):216–230.